Functional Assays for Specific Targeting and Delivery of RNA Nanoparticles to Brain Tumor
Cumulative progress in nanoparticle development has opened a new era of targeted delivery of therapeutics to cancer cells and tissue. However, developing proper detection methods has lagged behind resulting in the lack of precise evaluation and monitoring of the systemically administered nanoparticles. RNA nanoparticles derived from the bacteriophage phi29 DNA packaging motor pRNA have emerged as a new generation of drugs for cancer therapy. Multifunctional RNA nanoparticles can be fabricated by bottom-up self-assembly of engineered RNA fragments harboring targeting (RNA aptamer or chemical ligand), therapeutic (siRNA, miRNA, ribozymes, and small molecule drugs), and imaging (fluorophore, radiolabels) modules. We have recently demonstrated that RNA nanoparticles can reach and target intracranial brain tumors in mice upon systemic injection with little or no accumulation in adjacent healthy brain tissues or in major healthy internal organs. Herein, we describe various functional imaging methods (fluorescence confocal microscopy, flow cytometry, fluorescence whole body imaging, and magnetic resonance imaging) to evaluate and monitor RNA nanoparticle targeting to intracranial brain tumors in mice. Such imaging techniques will allow in-depth evaluation of specifically delivered RNA therapeutics to brain tumors.
This study aimed to investigate the role of S100B in NSCLC brain metastasis. The results showed that serum S100B correlated significantly with NSCLC brain metastasis (P
m Cherkasov Orphan nuclear receptor TLX (NR2E1) plays a critical role in the regulation of neural stem cells (NSC) as well as in the development of NSC-derived brain tumors. In the last years, new data have emerged implicating TLX in prostate and breast cancer. Therefore, inhibitors of TLX transcriptional activity may have a significant impact on the treatment of several critical malignancies. However, the TLX protein possesses a non-canonical ligand-binding domain (LBD), which lacks a ligand-binding pocket (conventionally targeted in case of nuclear receptors) that complicates the development of small molecule inhibit...
(Worcester Polytechnic Institute) Researchers at Worcester Polytechnic Institute and Albany Medical College, along with corporate partners GE Global Research and Acoustic MedSystems, have received a five-year, $3.5 million award from the National Institutes of Health through the National Cancer Institutes' Academic-Industrial Partnership program, to continue development of an innovative robotic system that, operating within an MRI scanner, can deliver a minimally invasive probe into the brain to destroy metastatic brain tumors with high-intensity therapeutic ultrasound under real-time guidance.
(University of California - San Francisco) In a new study published Nov. 13 in the journal eLife, UC San Francisco scientists report the first animal model of glioma -- the most aggressive and most common form of brain cancer in the US -- that can also be used to study the long-term effects of radiation therapy in tumor-bearing brains. Using this mouse model, the researchers showed that a drug that temporarily suppresses a key component of the brain's immune system can prevent radiation-associated cognitive decline.
ConclusionsThe results indicate that 6-MOMIPP is a novel microtubule disruptor that targets the colchicine binding site on β-tubulin to induce mitotic arrest and cell death. The ability of 6-MOMIPP to penetrate the blood–brain barrier and inhibit growth of glioblastoma xenografts suggests that it warrants further preclinical evaluation as poten tial small-molecule therapeutic that may have advantages in treating primary and metastatic brain tumors.
Conditions: Glioma; Glioma of Brain; Cancer; Pediatric Cancer; Pediatric Brain Tumor; Astrocytoma; Glioblastoma; Hemispheric Intervention: Other: Specialized tumor board recommendation Sponsors: University of California, San Francisco; Pacific Pediatric Neuro-Oncology Consortium Not yet recruiting
ConclusionPioglitazone was well tolerated by brain tumor patients undergoing RT. 45 mg is a safe dose to use in future efficacy trials.
This article is protected by copyright. All rights reserved.
ConclusionsWe found no evidence of reduced survival among glioma patients in relation to previous mobile phone use.
ConclusionsOur data suggested an action of RF –EMF by reducing immune cell invasion and glioblastoma cell apoptosis, at probably too low amplitude to impact survival. Further replication studies are needed to confirm these observations.